|
oncology |
4 |
|
therapeutics |
4 |
|
chinese |
2 |
|
genome-wide association study |
2 |
|
polygenic risk score |
2 |
|
prostate cancer |
2 |
|
single nucleotide polymorphism |
2 |
|
2014 international society of urological pathology grouping |
1 |
|
[-2]propsa |
1 |
|
[-2]propsa (p2psa) |
1 |
|
accelerometer |
1 |
|
active surveillance |
1 |
|
age |
1 |
|
aggressive |
1 |
|
aggressive prostate cancer |
1 |
|
androgen deprivation therapy (adt) |
1 |
|
ar signaling |
1 |
|
association |
1 |
|
atm |
1 |
|
auc |
1 |
|
benchmark |
1 |
|
benign prostatic hyperplasia |
1 |
|
benign prostatic hyperplasia (bph) |
1 |
|
bidirectional mendelian randomization |
1 |
|
biochemical recurrence |
1 |
|
bioinformatics |
1 |
|
biological age |
1 |
|
biomarker |
1 |
|
biopsy |
1 |
|
bladder cancer |
1 |
|
bph |
1 |
|
brca1 |
1 |
|
brca2 |
1 |
|
breast cancer |
1 |
|
cancer |
1 |
|
cancer screening |
1 |
|
cancer-specific mortality |
1 |
|
cancer-specific survival |
1 |
|
cannabis |
1 |
|
cardiovascular |
1 |
|
castration resistance |
1 |
|
castration-resistant prostate cancer |
1 |
|
causality |
1 |
|
ccrcc |
1 |
|
cftr |
1 |
|
chek2 |
1 |
|
chemokine receptor 4 (cxcr4) |
1 |
|
china |
1 |
|
china; prostate cancer; prostate health index; prostate volume |
1 |
|
chinapca |
1 |
|
chinese population |
1 |
|
chronic hepatitis b |
1 |
|
chronic hepatitis b (chb) |
1 |
|
clear cell renal cell carcinoma |
1 |
|
clinical decision-making |
1 |
|
cohort |
1 |
|
cohort study |
1 |
|
colorectal cancer |
1 |
|
comorbidity index |
1 |
|
copy number alteration |
1 |
|
copy number variation |
1 |
|
cost-effectiveness |
1 |
|
covid-19 |
1 |
|
cross-ancestry |
1 |
|
crpc |
1 |
|
cutoff |
1 |
|
cx3cl1 |
1 |
|
decipher |
1 |
|
diagnosis |
1 |
|
dna |
1 |
|
dna methylation |
1 |
|
dna repair |
1 |
|
dna repair genes |
1 |
|
e2f1 |
1 |
|
electronic health record |
1 |
|
emt |
1 |
|
enrichment |
1 |
|
epithelial-mesenchymal transition |
1 |
|
eqtl |
1 |
|
erk |
1 |
|
european |
1 |
|
exome array |
1 |
|
expression |
1 |
|
expression quantitative trait locus |
1 |
|
fam135a |
1 |
|
family history |
1 |
|
g135e |
1 |
|
g84e |
1 |
|
gender |
1 |
|
gene burden |
1 |
|
genetic |
1 |
|
genetic predisposition to disease |
1 |
|
genetic risk |
1 |
|
genetic risk score |
1 |
|
genetic score |
1 |
|
genetic testing |
1 |
|
genetics |
1 |
|
genistein |
1 |
|
genome wide association |
1 |
|
genome-wide association |
1 |
|
germline |
1 |
|
germline genetics |
1 |
|
germline mutation |
1 |
|
germline mutations |
1 |
|
germline variant |
1 |
|
gleason score |
1 |
|
grpr |
1 |
|
hepatitis b virus (hbv) |
1 |
|
hepatocellular carcinoma |
1 |
|
hernia |
1 |
|
high grade |
1 |
|
high-penetrance genes |
1 |
|
histology |
1 |
|
hoxb13 |
1 |
|
hsd3b1 |
1 |
|
immunohistochemistry |
1 |
|
incidence |
1 |
|
inflammation |
1 |
|
interaction |
1 |
|
intrahepatic and extrahepatic diseases |
1 |
|
irx4 |
1 |
|
itraq |
1 |
|
kidney cancer |
1 |
|
lethal prostate cancer |
1 |
|
lilra3 |
1 |
|
long noncoding rnas |
1 |
|
loss of function (lof) |
1 |
|
luts |
1 |
|
machine learning |
1 |
|
magnetic stimulation |
1 |
|
male |
1 |
|
mapk |
1 |
|
marital status |
1 |
|
masld/metald/ald |
1 |
|
medical oncology |
1 |
|
mendelian randomization |
1 |
|
meta-analysis |
1 |
|
methylation |
1 |
|
modifiable lifestyle behavior |
1 |
|
mortality |
1 |
|
multi-parametric magnetic resonance imaging |
1 |
|
multiomic analysis |
1 |
|
mutation |
1 |
|
myc |
1 |
|
nafld |
1 |
|
nephrectomy |
1 |
|
nri |
1 |
|
oncoscan |
1 |
|
p2psa |
1 |
|
paget disease |
1 |
|
pan-cancer |
1 |
|
pancreatic adenocarcinoma |
1 |
|
pancreatic cancer |
1 |
|
partial nephrectomy |
1 |
|
pathologic |
1 |
|
pathology upgrading |
1 |
|
pathway analysis |
1 |
|
pegylated interferon α |
1 |
|
pegylated interferon-alpha (pegifnα) |
1 |
|
pelvic floor muscle training (pfmt) |
1 |
|
perineural invasion |
1 |
|
physical activity |
1 |
|
plasma |
1 |
|
polygenic score |
1 |
|
polymorphism |
1 |
|
polymorphism, single nucleotide |
1 |
|
positive cores |
1 |
|
ppfibp2 |
1 |
|
precision medicine |
1 |
|
probe panel |
1 |
|
prognosis |
1 |
|
prognosis model |
1 |
|
prognostic |
1 |
|
prolaris |
1 |
|
prostate |
1 |
|
prostate biopsy |
1 |
|
prostate cancer (pca) |
1 |
|
prostate cancer death |
1 |
|
prostate cancer progression |
1 |
|
prostate health index |
1 |
|
prostate health index (phi) |
1 |
|
prostate imaging reporting and data system |
1 |
|
prostate neoplasm |
1 |
|
prostate screening |
1 |
|
prostate volume |
1 |
|
prostate-specific antigen |
1 |
|
prostatectomy |
1 |
|
prostatic hyperplasia |
1 |
|
prostatic neoplasms |
1 |
|
protein s100a8 |
1 |
|
protein s100a9 |
1 |
|
proteomics |
1 |
|
psa |
1 |
|
pyroptosis subtype |
1 |
|
radical prostatectomy (rp) |
1 |
|
radiologic |
1 |
|
radiomics |
1 |
|
ran |
1 |
|
rare mutation |
1 |
|
receiver operating curve |
1 |
|
receiver operating curve (roc) |
1 |
|
reciprocal relationship |
1 |
|
recurrence |
1 |
|
renal cancer |
1 |
|
renal cell cancer |
1 |
|
renal cell carcinoma |
1 |
|
risk assessment |
1 |
|
risk calculator |
1 |
|
risk factor |
1 |
|
rna |
1 |
|
rna profiling |
1 |
|
rs2853669 |
1 |
|
rural population |
1 |
|
screening interval |
1 |
|
seer database |
1 |
|
sepsis |
1 |
|
serum biomarker |
1 |
|
single nucleotide polymorphism (snp) |
1 |
|
single nucleotide polymorphisms |
1 |
|
single-nucleotide polymorphism (snp) |
1 |
|
snp |
1 |
|
snps |
1 |
|
socioeconomic factors |
1 |
|
somatic cna |
1 |
|
somatic genetic alterations |
1 |
|
srd5a1 protein, human |
1 |
|
srd5a2 protein, human |
1 |
|
steroid hormone metabolism |
1 |
|
stress urinary incontinence (sui) |
1 |
|
surgical margins |
1 |
|
surgical specimen |
1 |
|
survival |
1 |
|
survival analysis |
1 |
|
susceptibility |
1 |
|
telomerase reverse transcriptase |
1 |
|
tert |
1 |
|
testosterone |
1 |
|
thyroid cancer |
1 |
|
translational genomics |
1 |
|
tumor marker |
1 |
|
tumor size |
1 |
|
urinary biomarker |
1 |
|
urine |
1 |
|
urological emergency |
1 |
|
validity |
1 |
|
volume |
1 |
|
watchful waiting |
1 |
|
xanthogranulomatous pyelonephritis |
1 |
|
zhx2 |
1 |
